Individual trends in LDL-C control in patients with previous myocardial infarction

Ródenas, Eduardo; Escalona, Roxana; Pariggiano, Ivana; Oristrell, Gerard; Miranda, Berta; Belahnech, Yassin; Soriano, Toni; Rello, Pau; Gordon, Blanca; Barrabés, José A.; Garcı́a-Dorado, David; Bañeras, Jordi

doi:10.1016/j.rccl.2019.10.001

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with these results, Ribas et al reported that just 45% of ACS patients reached LDL levels <70 mg/dL in the 122 days after the ACS, and that the use of Masana's recommendations improved the management and treatment planification in these patients ( 11 ). In addition, Ródenas et al observed that only one third of patients who had suffered a previous myocardial infarction had LDL levels <70 mg/dL during a follow-up period between 2013 and 2018 ( 32 ). These analyses considered a relatively small population of patients, but it is expected that our study will include more than 2,600 patients with ASCVD.…”

Section: Discussionmentioning

confidence: 99%

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Barrios

Ruiz

Cerezo

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAtherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs. In Spain, the evidence about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study. The aim of this study is to describe the demographic and clinical characteristics, comorbidities, and concomitant medication of patients with ASCVD and hypercholesterolemia and of patients with familial hypercholesterolemia (FH). The use of healthcare resources and costs associated to the management of these diseases after their diagnosis were also considered.MethodsThis is an observational and retrospective study, based on the BIG-PAC® database, which includes the electronic medical registries (EMRs) of 1.8 million people from 7 Autonomous Communities in Spain (including public primary care centers and hospitals). The study includes patients who had a new or recurrent episode of ASCVD during the recruitment period (from 01/01/2017 to 31/12/2018). The index date will be defined as the date of the ASCVD event, and the follow-up period will be 24 months. According to their first diagnosis in the database, patients will be classified as ASCVD (5 groups: stable/unstable angina, acute myocardial infarction, ischemic stroke, transient ischemic attack, and peripheral arterial disease) or FH.DiscussionThis study aims to analyze the treatment patterns and use of healthcare resources of ASCVD and FH in Spain. The prevalence of these disorders will also be estimated. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Barrios

Ruiz

Cerezo

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Despite this recommendation, managing LDL-C levels remains challenging worldwide and within Canada. 8 , 9 , 10 Indeed, Aref-Eshghi et al. found that 68.6% of high-risk patients (including patients with atherosclerosis, most patients with diabetes, and those with a Framingham risk score ≥ 20%) in Canadian primary care settings had LDL-C levels in excess of guideline-recommended thresholds.…”

mentioning

confidence: 99%

“…conducted a study in a primary care outpatient setting in Spain and found that only one third of outpatients with a previous myocardial infarction were maintaining LDL-C levels below threshold. 10 …”

mentioning

confidence: 99%

Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients

Taboun¹,

Naik²,

Brown³

et al. 2023

CJC Open

View full text Add to dashboard Cite

Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential

Brandts

Ray

2020

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Individual trends in LDL-C control in patients with previous myocardial infarction

Cited by 3 publications

References 29 publications

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients

Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential

Contact Info

Product

Resources

About